Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Dr. Marc Siegel appears in 1 tracked Biotech story from August 18, 2026.
Last mentioned: 5d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Dr. Marc Siegel appears in 1 tracked Biotech story from August 18, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Marc Siegel. Shared-story counts are live from our verified record — not editorial picks.
Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Source: fox7austin.com · fox32chicago.com
Dr. Marc Siegel is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
